Evidence map›Paper›PMID 37298359›Full record

ArticleInternational journal of molecular sciences2023

The Lysyl Oxidase G473A Polymorphism Exacerbates Oral Cancer Development in Humans and Mice.

Yaser Peymanfar, Faranak Mahjour, Neha Shrestha, Ana de la Cueva, Ying Chen, Shengyuan Huang, Kathrin H Kirsch, Xiaozhe Han, Philip C Trackman

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Pathogenesis and Therapy of Oral Carcinogenesis.International journal of molecular sciences · 2024
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yaser PeymanfarThe Forsyth Institute, 245 First Street, Cambridge, MA 02142, USA.ORCID 0000-0002-5793-0474
Faranak MahjourDepartment of Translational Dental Medicine, Henry M. Goldman School of Dental Medicine, Boston University, 700 Albany Street, Boston, MA 02118, USA.
Neha ShresthaDepartment of Translational Dental Medicine, Henry M. Goldman School of Dental Medicine, Boston University, 700 Albany Street, Boston, MA 02118, USA.
Ana de la CuevaDepartment of Biochemistry, School of Medicine, Boston University, 72 East Concord Street, Boston, MA 02118, USA.
Ying ChenThe Forsyth Institute, 245 First Street, Cambridge, MA 02142, USA.
Shengyuan HuangDepartment of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University, Fort Lauderdale, FL 33314, USA.
Kathrin H KirschDepartment of Biochemistry, School of Medicine, Boston University, 72 East Concord Street, Boston, MA 02118, USA.
Xiaozhe HanDepartment of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University, Fort Lauderdale, FL 33314, USA.ORCID 0000-0001-8357-1471
Philip C TrackmanThe Forsyth Institute, 245 First Street, Cambridge, MA 02142, USA.ORCID 0000-0001-5064-614X
Boston University · USNova Southeastern University · US

Funding

Regulatory B Cells in the Amelioration of Immune-Mediated Periodontal DiseaseR01DE025255 · NIDCR · NOVA SOUTHEASTERN UNIVERSITY · PI HAN, XIAOZHE · 2015 to 2025
$5.8M
Osteoblast Dopamine Receptor Mediates Diabetic Bone DiseaseR21AR077260 · NIAMS · ADA FORSYTH INSTITUTE, INC. · PI TRACKMAN, PHILIP C · 2021 to 2022
$479k
Cellular or Extracellular Targeting of Lysyl Oxidase Propeptide for Oral CancerR21DE023973 · NIDCR · BOSTON UNIVERSITY MEDICAL CAMPUS · PI TRACKMAN, PHILIP C · 2014 to 2015
$450k
NIAMS NIH HHS R21 AR077260NIAMS NIH HHS R21AR077260-01A1NIDCR NIH HHS R01 DE025255NIDCR NIH HHS R21 DE023973
6 · The paper itself

Abstract

Oral cancer is primarily squamous-cell carcinoma with a 5-year survival rate of approximately 50%. Lysyl oxidase (LOX) participates in collagen and elastin maturation. The propeptide of LOX is released as an 18 kDa protein (LOX-PP) in the extracellular environment by procollagen C-proteinases and has tumor-inhibitory properties. A polymorphism in the propeptide region of

Indexed as

Mouth NeoplasmsProtein-Lysine 6-OxidaseAnimalsCarcinogensCollagenExtracellular Matrix ProteinsHumansMicePolymorphism, GeneticCarcinogensCollagenExtracellular Matrix ProteinsLOX protein, humanLox protein, mouseProtein-Lysine 6-Oxidase4 NQOextracellular matrixhumanlysyl oxidasemouse modeloral cancerpathogenesispolymorphismtumor suppressor

Identifiers

PMID37298359
PMCPMC10254048
OpenAlexW4378619249

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.